---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Pharmacokinetics"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Pharmacokinetics. Topics: Route: delivery into cerebrospinal fluid and systemic exposure, Biodistribution of TSHA-102 in nonhuman primate brain and spinal cord after lumbar intrathecal infusion, Comparison of lumbar intrathecal and intracisterna magna delivery, Dose dependence and change over time in brain vector genome levels, and 3 further topics. 7 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/pharmacokinetics"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Pharmacokinetics

<a id="heading-2.1.2.6.3"></a>

## 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

### Route: delivery into cerebrospinal fluid and systemic exposure

> “Delivery of recombinant adeno-associated virus serotype 9 (rAAV9) into cerebrospinal fluid bypasses the blood–brain barrier and can permit efficient brain tissue transduction.”
> “As with intracisterna magna (ICM) or intra-cerebroventricular (ICV) instillation, IT delivery bypasses the blood–brain barrier, reduces vector load in systemic circulation, and minimizes risk of interference of pre-existing anti-AAV antibodies”
> “Uniquely, it offers the possibility of outpatient treatment with no specialized surgical equipment.”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-2"></a>

### Biodistribution of TSHA-102 in nonhuman primate brain and spinal cord after lumbar intrathecal infusion

> “CNS biodistribution showed generally similar vector genome levels in all CNS tissues tested, with a low value observed at the 90-day point for the cervical spinal cord”
> “Across four NHP biodistribution studies, at times ranging from 1 month to 1 year post-treatment, lumbar IT administration led to widespread, stable, and generally uniform vector genome levels throughout the brain and spinal cord.”
> “Across five NHP biodistribution studies, rAAV9 DNA was quantifiable in all brain and CNS tissues examined, irrespective of RoA (IT versus ICM) or time post-necropsy, at typical levels exceeding 1 vg copy per brain cell at the highest doses.”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-3"></a>

### Comparison of lumbar intrathecal and intracisterna magna delivery

> “At comparable doses and times, IT and ICM delivery led to widespread and consistent distribution of vector genomes, approximating 1 vg/diploid host genome throughout the brain at the higher doses tested.”
> “The ratio of ICM to lumbar IT vector biodistribution in various brain and spinal cord tissues ranged from <1 (temporal lobe) to ~5 (cerebellum).”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-4"></a>

### Dose dependence and change over time in brain vector genome levels

> “Comparing TSHA-102 versus TSHA-105 data, both with lumbar IT delivery, the four-fold increase in input dose with TSHA-105 was associated with a ~2.5-fold increase in vector genome levels detected in brain tissues; this difference was seen at both necropsy time points.”
> “This analysis also indicated higher brain vector genome levels in Day ≥180 necropsy samples, relative to Day 90 samples, in animals that had been treated by lumbar IT dosing.”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-5"></a>

### Limitations reported for the lumbar intrathecal route

> “However, some studies have suggested the lumbar IT route leads to limited transduction of brain tissues”
> “The fact that these studies were conducted separately, according to different protocols, limits the precision of any quantitative claims that can be made for rAAV9 biodistribution from this data set”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-6"></a>

### Administration and monitoring conditions of the nonclinical biodistribution studies

> “IT injection was to the L4-5 or L5-6 intervertebral space, with the needle tip angled slightly cranially.”
> “Injections (2.5 mL total volume) were performed with animals prone or recumbent, not in the Trendelenburg position.”
> “No immunosuppression was used.”

Source: [Haque et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13167494/)

<a id="topic-2.1.2.6.3-7"></a>

### Detection of vector DNA in all tissues analyzed at 90 and 180 days

> “At 90 days and 180 days, TSHA-102 (lumbar IT) DNA was detected in all tissues analyzed post-lumbar IT infusion and biodistribution was consistent across all tissues (Figure 3)”
> “Following lumbar IT delivery, vector DNA levels were dose-dependent; the 4-fold dose increase was associated with a 1.5–2.5-fold vector copy number increase in brain tissues (Figure 5)”

Source: [Haque et al. (2025)](https://tayshagtx.com/wp-content/uploads/rAAV9-Vector-Biodistribution-in-Brain-and-Spinal-Cord-via-Lumbar-Intrathecal-Infusion-in-Nonhuman-Primates-NHP-Assessing-the-Administration-Route-Leveraged-in-TSHA-102-Rett-Syndrome-Clinical-Trials.pdf)

<a id="topic-2.1.2.6.3-8"></a>

### Pharmacokinetic measurements in humans

No evidence found.

Additional sources: [Haque et al. (2024)](https://tayshagtx.com/wp-content/uploads/Broad-CNS-Biodistribution-of-AAV9-based-Gene-Therapies-Delivered-by-Intrathecal-Lumbar-Puncture-in-Non-Human-Primates.pdf)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
